Outlook Therapeutics, Inc. (OTLK) Stock Score, Valuation & Financial Research
Outlook Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 13/100.
Quick answer for OTLK
Outlook Therapeutics, Inc. currently has a Wall Street Score of 13/100. The stored market price is $0.65. Its financial score is 1/100. Its valuation score is 0/100. The latest WSS change is -0.6 points. These figures are a research snapshot, not a buy or sell recommendation.
What Outlook Therapeutics, Inc. does
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located i
OTLK financial snapshot
- Wall Street Score:
- 13/100
- Current price:
- $0.65
- Market capitalization:
- $122.0M
- Revenue:
- $-1.2M
- Net income:
- $-61.1M
- Free cash flow:
- $-51.8M
- Cash:
- $11.2M
- Total debt:
- $18.4M
- EPS:
- -1.87
- Financial score:
- 1/100
- Valuation score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -1.8%.
- Free cash flow is $-51.8M, showing cash burn in the current stored period.
- The balance sheet shows $11.2M of cash versus $18.4M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.6 points: OTLK decreased 0.6 points because Debt declined by 10 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
Questions worth answering for OTLK
These questions are derived from the company's current stored financial and score data so the page adds company-specific research context instead of treating the headline score as a stand-alone conclusion.
- What is driving OTLK's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
- How long can OTLK fund negative free cash flow using its current cash position before it may need more debt or new shares?
- Does OTLK's balance between cash and debt leave enough flexibility if business conditions weaken?
- What specifically needs to improve for OTLK to reach sustainable profitability?
- What future growth or profitability would be needed to justify OTLK's current valuation?
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 1/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-19.
Research-input completeness: 82% of the scoring inputs required for this public page are currently available.
How to research OTLK
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.